Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Non-Proliferative Diabetic Retinopathy Market Forecast Highlighting Growth From $3.05 Billion To $3.97 Billion
The market for non-proliferative diabetic retinopathy has experienced robust expansion lately, projecting a rise from $2.83 billion in 2025 to $3.06 billion in 2026, reflecting a compound annual growth rate of 8.0%. This growth during the past period stems from factors such as the widespread incidence of diabetes, scant awareness regarding retinal complications, a preference for traditional laser therapy, limited uptake of intravitreal injections, and an inadequate screening infrastructure.
The market for non-proliferative diabetic retinopathy is poised for noteworthy expansion, projected to reach $3.98 billion by 2030, reflecting a compound annual growth rate of 6.8%. This anticipated increase stems from several key drivers, including the escalating incidence of diabetic retinopathy, a greater uptake of anti-VEGF and corticosteroid treatments, the proliferation of eye care facilities and specialized centers, advancements in retinal imaging technology, and enhanced patient education initiatives coupled with early detection efforts. Dominating the landscape during this period will be the increasing use of anti-VEGF therapies specifically for non-proliferative diabetic retinopathy, a rise in intraocular steroid injections, the expanded application of sophisticated laser surgical methods, a broader utilization of vitrectomy procedures, and the growing incorporation of artificial intelligence in retinal imaging and diagnostic processes.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp
Non-Proliferative Diabetic Retinopathy Market Expansion Drivers: What Is Shaping Future Growth?
The expanding incidence of diabetes is anticipated to be a key factor in advancing the non-proliferative diabetic retinopathy market. Diabetes is a persistent condition affecting metabolism, marked by excessively high blood sugar levels stemming from either insufficient insulin production by the pancreas or the body’s cells failing to respond effectively to insulin. Factors contributing to diabetes include inactive lifestyles, poor eating practices, and inherited tendencies. This condition triggers non-proliferative diabetic retinopathy by harming the retina’s blood vessels, largely a consequence of sustained high glucose concentrations in the blood, ultimately leading to visual disturbances and possible blindness. To illustrate, in June 2024, data from the National Health Service in the UK revealed that in 2023, over half a million (over 549,000) more individuals in England were identified as being at risk of developing type 2 diabetes, raising the total number of people with pre-diabetes, or non-diabetic hyperglycemia, on GP registers to 3,615,330. This figure shows a substantial jump from the 3,065,825 recorded in 2022, indicating a growth of almost 20%. Consequently, the escalating rate of diabetes directly fuels the expansion of the non-proliferative diabetic retinopathy market.
Non-Proliferative Diabetic Retinopathy Market Segment Landscape: Which Areas Lead Market Development?
The non-proliferative diabetic retinopathy market covered in this report is segmented –
1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea), Pegaptanib (Macugen)
2) By Intraocular Steroid Injection: Triamcinolone Acetonide, Dexamethasone Implant (Ozurdex), Fluocinolone Acetonide Implant (Iluvien)
3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy (PPV), Membrane Peeling Vitrectomy, Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)
Non-Proliferative Diabetic Retinopathy Market Strategic Trends: What Is Defining The Next Phase Of Growth?
In the landscape of non-proliferative diabetic retinopathy (NPDR) therapeutics, leading enterprises are prioritizing the advancement of sophisticated clinical strategies, specifically the enrollment in Phase 3 registrational trials, to bolster the validation of their treatments, accumulate strong supporting data, and facilitate the necessary regulatory approvals for novel NPDR interventions. The process of Phase 3 registrational trial enrollment signifies the official commencement and assignment of participants to a critical, advanced-stage clinical evaluation intended to yield thorough information on the effectiveness and safety profile required for the market release of a medicinal product. As an illustration, November 2025 saw Ocular Therapeutix, an American biopharmaceutical firm dedicated to ophthalmic conditions, report the initial patient randomization within the HELIOS-3 Phase 3 registrational study, which is investigating AXPAXLI (OTX-TKI) for NPDR. AXPAXLI is an experimental biodegradable intravitreal hydrogel containing axitinib, a substance that inhibits the tyrosine kinase enzyme and possesses anti-angiogenic properties, formulated to deliver ongoing therapeutic benefits through reduced injection frequency. The HELIOS-3 study, conjointly with HELIOS-2, is employing a new primary endpoint measuring at least a 2-step improvement on the Diabetic Retinopathy Severity Score (DRSS) and incorporates individuals diagnosed with non-center-involved diabetic macular edema (non-CI-DME), thereby presenting AXPAXLI as a candidate for substantially improving long-term and effective NPDR care.
Non-Proliferative Diabetic Retinopathy Market Industry Leaders And Market Competition
Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Kowa Company Ltd.
Access The Complete Non-Proliferative Diabetic Retinopathy Market Report:
Non-Proliferative Diabetic Retinopathy Market Leading Geography: Which Region Generates The Most Revenue?
North Americawas the largest region in the non-proliferative diabetic retinopathy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
